



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Total Voting Rights

London: Monday, 4 January 2010: For information purposes, Chi-Med hereby notifies the market that as at 31 December 2009, the issued share capital of the Company consisted of 51,279,174 ordinary shares of US\$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 51,279,174 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the FSA's Disclosure and Transparency Rules.

Ends

Enquiries

Chi-Med
Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson
Anthony Carlisle
David Dible

Telephone: +44 (0) 20 7638 9571
+44 (0) 7973 611 888
+44 (0) 7967 566 919

Lazard & Co., Ltd.
Paul Gismondi
Nick Fowler

Telephone: +44 (0) 20 7187 2000

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.